...
首页> 外文期刊>Clinical ophthalmology >Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
【24h】

Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study

机译:双聚合物羟丙基瓜尔和含透明质酸润滑剂眼镜治疗干眼症的疗效和安全性:随机双掩盖临床研究

获取原文
           

摘要

Background: An artificial-tear formulation containing the dual polymers hydroxypropyl guar (HPG) and hyaluronic acid (HA) is approved for the treatment of dry-eye disease (DED). The?present study compared the efficacy and safety of the HPG-HA dual-polymer formulation vs a sodium hyaluronate (SH)-containing artificial-tear formulation in patients with DED. Methods: In a prospective, 6-week, multicenter, double-masked, parallel-group study, patients with DED aged ≥18 years and total ocular surface staining (TOSS) score ≥4 and ≤9 were randomized (1:1) to receive either HPG-HA or SH four times a day for 42 days. Changes from baseline in TOSS (primary end point), impact of dry eye on everyday life (IDEEL) treatment-satisfaction scores (effectiveness and inconvenience), and tear-film breakup time (TFBUT) at day 42 were assessed using a fixed-sequence testing strategy. Noninferiority was assessed on the primary end point based on the upper limit of two-sided 95% CIs for mean treatment difference (HPG-HA or SH) 2 units. Results: In total, 99 patients were randomized (HPG-HA, n= 50; SH, n= 49). At day 42, the least square (LS) mean ± SE change from baseline in TOSS was -1.16±0.24 and -0.92±0.23 in the HPG-HA and SH groups, respectively, and the treatment difference was -0.24±0.33 (95% CI -0.90 to 0.42). Noninferiority was demonstrated as the upper limit of the 95% CI was 2 units. LS mean change from baseline at day 42 for HPG-HA vs SH was -3.18 ( P =0.4817) in IDEEL treatment-effectiveness scores,?-12.56 ( P =0.0001) in treatment-inconvenience scores, and 0.30 seconds ( P =0.5789) in TFBUT. Conclusion: The HPG-HA dual-polymer formulation was noninferior to the SH lubricant eyedrops for improvement in ocular surface staining in DED. HPG-HA did not show improvement over SH in IDEEL treatment-satisfaction scores. No new safety findings were reported.
机译:背景:含有双聚合物羟丙基瓜尔(HPG)和透明质酸(HA)的人工撕裂制剂被批准用于治疗干眼症(DED)。本研究比较了HPG-HA双聚合物制剂的功效和安全性与透明质酸钠(SH)型人工撕裂制剂患者患者患者。方法:在预期,6周,多中心,双掩盖,并行群体研究中,患者≥18岁≥18岁,染色的总表面染色(折腾)得分≥4和≤9分机(1:1)至每天4次接收HPG-HA或SH 42天。从折腾(主要终点)中的基线变化,使用固定序列评估日常生活(IDEEL)对日常生活的影响(IDEEL)处理 - 满意度评分(有效性和不便)和泪膜分发时间(TFBUT)的影响测试策略。基于双面治疗差(HPG-HA或SH)2单位的双面95%CI的上限评估非终点的非终点。结果:总共99名患者随机化(HPG-HA,N = 50; SH,N = 49)。在第42天,在折腾中的基线最小二乘(LS)平均值±SE在HPG-HA和SH组中的基线变化为-1.16±0.24和-0.92±0.23,并且治疗差异为-0.24±0.33(95 %CI -0.90至0.42)。由于95%CI的上限被证实了非血小效性<2单位。 LS在IDEEL治疗效果评分中的第42天在第42天从基线改变为-3.18(p = 0.4817),α - 12.56(p = 0.0001)治疗 - 不便等待,0.30秒(p = 0.5789 )在TFBUT中。结论:HPG-HA双聚合物配方对SH润滑剂滴眼剂的改善,在DED中的眼表面染色。 HPG-HA在意甲治疗满意度评分中没有表现出SH的改善。没有报告新的安全结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号